Health ProductsNotice to Hospitals

Archived – Propofol Contraindicated for Sedation in Pediatric Patients Receiving Intensive Care

· Published by Health Canada · Official notice

Details

Alert type: Notice to Hospitals
Category: Drugs, Affects children, pregnant or breast feeding women
Issue: New safety information
Audience: Hospitals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from the Marketed Health Products and Therapeutic Products Directorates, Health Canada.

Notice about Health Canada advisories

[Text of letter begins]

Notice to Hospitals
Important Drug Safety Information

July 10, 2002

Update on the Use of Propofol - PROPOFOL CONTRAINDICATED FOR SEDATION IN PEDIATRIC PATIENTS RECEIVING INTENSIVE CARE

Following consultation with Health Canada, all licenced providers of propofol are revising the Contraindication and Dosage and Administration Sections of the Product Monograph for propofol to include: Propofol is contraindicated for the sedation of children 18 years or younger receiving intensive care

The Marketed Health Products and Therapeutic Products Directorates (MHPD and TPD) wish to draw your attention to 6 Canadian reports of a constellation of serious adverse events that occurred in children who received propofol infusions in an ICU setting. Three of the six cases had a fatal outcome, and all cases were characterized by metabolic acidosis, hemodynamic instability, and cardiac conduction abnormalities. Similar findings were first reported in the literature in 1992 in children who had received prolonged propofol infusions in the ICU.Footnote 1 Since the 1992 publication, several similar reports have been published,Footnote 2, Footnote 3, Footnote 4, Footnote 5, Footnote 6 including an article that summarized 18 cases of children who received propofol infusions and suffered serious adverse events, including death.Footnote 7

The identification, characterization, and management of drug-related adverse events is dependent on the active participation of health care professionals in adverse drug reaction reporting programmes. Health care professionals are asked to report any suspected adverse reactions in patients receiving propofol to the Marketed Health Products Directorate at the following address:

Any suspected adverse drug reactions can be reported to:

Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0201C2
Ottawa, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals and Specialties, or on the TPD web site, along with the ADR Guidelines.

References

Footnote 1

Parke, T.J. et al. 1992. British Medical Journal. 305: 613-616.

Return to footnote 1 referrer

Footnote 2

Cray, S.H., et al. 1998. Critical Care Medicine, 1998: 2087-2092.

Return to footnote 2 referrer

Footnote 3

Hanna, J.P., and Ramundo, M.L. 1998. Neurology, 50: 301-303.

Return to footnote 3 referrer

Footnote 4

Mehta, M., et al. 1999. The Lancet. 354: 865-867.

Return to footnote 4 referrer

Footnote 5

Cannon M.L., et al. 2001. Journal of Neurosurgery, 95: 925-956.

Return to footnote 5 referrer

Footnote 6

Wolf, A., et al. 2001. The Lancet, 357: 606-607.

Return to footnote 6 referrer

Footnote 7

Bray, R.J.1998. Paediatric Anaesthesia, 8: 491-499.

Return to footnote 7 referrer

[Text of letter ends]

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime